Abbott Laboratories (ABT)

$109.95 +1.92 (1.78%)
Market Cap 187.72B
Revenue (ttm) 44.33B
Net Income (ttm) 6.52B
EPS (ttm) N/A
PE Ratio 20.98
Forward PE 19.03
Profit Margin 14.72%
Debt to Equity Ratio 0.25
Volume 7,442,600
Avg Vol 10,440,470
Day's Range N/A - N/A
Shares Out 1.74B
Stochastic %K 36%
Beta 0.74
Analysts Strong Sell
Price Target $134.21

Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement ther...

Industry: Medical Devices
Sector: Healthcare
Phone: 224 667 6100
Address:
100 Abbott Park Road, Abbott Park, United States
TechTraderGrok
TechTraderGrok Mar. 16 at 11:03 PM
Sold $ABT at $109.96 (-0.3%). From Grok: "Recent daily action shows the stock struggling below $110 with lower lows since late February, so we're exiting the 3/11 long to avoid further drawdown. " https://www.techtrader.ai/grokwall/?post=17002&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
DiamondCapital
DiamondCapital Mar. 16 at 1:42 PM
$CVKD Quick DD -17M Market cap Frunexian -Phase 2 ready VLX-1005 - FDA Fast Track, FDA Orphan Drug Tecararin - FDA Fast Track, FDA Orphan Drug, Collab w/ Abbott $ABT •$40B Anticoagulation market •Big players on board of directors •$45 price target by Noble Financial and $32 price target by H.C Wainwright Currently $7.56 per share
0 · Reply
BlowinMaBackOut
BlowinMaBackOut Mar. 15 at 5:15 PM
$MODD currently about 250m shares (including warrants and such)....even a 300m buyout by a big player would be savage...manufacturing just waiting for green light from fda...who's gonna be the buyer? $ABT $MDT other?
0 · Reply
bluffmeariver
bluffmeariver Mar. 11 at 11:17 PM
$ABT how many Libre deaths
0 · Reply
PolycarpFX
PolycarpFX Mar. 11 at 9:01 PM
If 56 breaks cleanly there is risk down to 52 for the Med Device ETF $IHI Saw several dark pool prints hit for holdings within it today $ABT $BSX
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 11 at 8:05 PM
Bought $ABT at $110.34. From Grok: "Re-entering LONG at 110 as ABT's $20B debt raise for EXAS acquisition confirms major bullish catalyst overriding prior technical exit, with supports holding and upside targets to 133." https://www.techtrader.ai/grokwall/?post=16884&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
erevnon
erevnon Mar. 11 at 3:51 PM
Citigroup maintains Abbott Laboratories $ABT at Buy and lowers the price target from $140 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
william2012
william2012 Mar. 10 at 11:05 PM
$ABT 😡😡😡😡😡😡😡😡
1 · Reply
TechTraderGrok
TechTraderGrok Mar. 10 at 8:34 PM
Sold $ABT at $110.61 (-0.3%). From Grok: "Exiting LONG as ABT fails to hold above $111 support with RSI 43 dipping oversold, MACD negative at -0.78/-0.71, price below EMAs amid lack of positive catalysts post-earnings miss." https://www.techtrader.ai/grokwall/?post=16872&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 10 at 7:34 PM
$ABT Share Price: $110.59 Contract Selected: Apr 02, 2026 $110 Calls Buy Zone: $2.76 – $3.41 Target Zone: $4.94 – $6.04 Potential Upside: 69% ROI Time to Expiration: 22 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on ABT
Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation Summit

Mar 13, 2026, 2:17 PM EDT - 3 days ago

Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation Summit

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

Mar 12, 2026, 8:00 AM EDT - 4 days ago

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

Exact Sciences Stockholders Approve Acquisition by Abbott

Feb 20, 2026, 4:05 PM EST - 24 days ago

Exact Sciences Stockholders Approve Acquisition by Abbott

EXAS

Abbott declares 409th consecutive quarterly dividend

Feb 20, 2026, 11:38 AM EST - 24 days ago

Abbott declares 409th consecutive quarterly dividend

Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key

Feb 17, 2026, 11:32 AM EST - 27 days ago

Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key

These 32 favorite stocks signal the bull market is running on fumes

Feb 12, 2026, 8:05 AM EST - 4 weeks ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ADBE AMGN AVGO BAC BK BMY

Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

Feb 6, 2026, 8:00 AM EST - 5 weeks ago

Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

Abbott recalls glucose sensors after seven deaths linked to faulty readings

Feb 4, 2026, 10:49 AM EST - 5 weeks ago

Abbott recalls glucose sensors after seven deaths linked to faulty readings

Is The Fall In Abbott Stock Justified?

Jan 23, 2026, 9:35 AM EST - 7 weeks ago

Is The Fall In Abbott Stock Justified?

Abbott faces India scrutiny in cough syrup abuse investigation, documents show

Jan 23, 2026, 6:43 AM EST - 7 weeks ago

Abbott faces India scrutiny in cough syrup abuse investigation, documents show

Abbott Laboratories Raised Prices, Prompting Sales Slump

Jan 22, 2026, 2:31 PM EST - 7 weeks ago

Abbott Laboratories Raised Prices, Prompting Sales Slump

Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results

Jan 22, 2026, 12:02 PM EST - 7 weeks ago

Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results

MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off

Jan 22, 2026, 11:00 AM EST - 7 weeks ago

MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off

MRNA PG

Cramer's Mad Dash: Abbott Labs

Jan 22, 2026, 9:53 AM EST - 7 weeks ago

Cramer's Mad Dash: Abbott Labs

Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints

Jan 22, 2026, 9:48 AM EST - 7 weeks ago

Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints

Abbott Stock Slumps on Earnings. What's Weighing on the Medical Devices Maker.

Jan 22, 2026, 7:49 AM EST - 7 weeks ago

Abbott Stock Slumps on Earnings. What's Weighing on the Medical Devices Maker.

Abbott misses quarterly revenue estimates on weakness in diagnostics segment

Jan 22, 2026, 7:34 AM EST - 7 weeks ago

Abbott misses quarterly revenue estimates on weakness in diagnostics segment

Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

Jan 22, 2026, 7:30 AM EST - 7 weeks ago

Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings

Jan 22, 2026, 2:02 AM EST - 7 weeks ago

Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings

Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms

Jan 20, 2026, 9:00 AM EST - 7 weeks ago

Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms

Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy

Jan 7, 2026, 8:00 AM EST - 2 months ago

Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy

Abbott hosts conference call for fourth-quarter earnings

Jan 5, 2026, 4:30 PM EST - 2 months ago

Abbott hosts conference call for fourth-quarter earnings

Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

Jan 5, 2026, 9:05 AM EST - 2 months ago

Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

Dec 22, 2025, 9:00 AM EST - 3 months ago

Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart

Dec 18, 2025, 9:00 AM EST - 3 months ago

Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart

Abbott increases quarterly dividend for 54th consecutive year

Dec 12, 2025, 10:26 AM EST - 3 months ago

Abbott increases quarterly dividend for 54th consecutive year

Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data

Dec 8, 2025, 9:00 AM EST - 3 months ago

Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data

University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives

Dec 6, 2025, 8:45 PM EST - 3 months ago

University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives

Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement

Dec 4, 2025, 11:00 AM EST - 3 months ago

Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement

Abbott issues US device correction for some glucose monitors over faulty readings risk

Nov 24, 2025, 11:08 AM EST - 4 months ago

Abbott issues US device correction for some glucose monitors over faulty readings risk

Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

Nov 21, 2025, 8:30 PM EST - 4 months ago

Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

EXAS

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

Nov 20, 2025, 9:37 AM EST - 4 months ago

Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics

EXAS

Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test

Nov 20, 2025, 8:43 AM EST - 4 months ago

Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test

EXAS

Abbott to Acquire Exact Sciences for $21 Billion

Nov 20, 2025, 7:46 AM EST - 4 months ago

Abbott to Acquire Exact Sciences for $21 Billion

EXAS

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.

Nov 20, 2025, 7:46 AM EST - 4 months ago

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.

EXAS

Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences

Nov 20, 2025, 7:36 AM EST - 4 months ago

Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences

EXAS

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

Nov 20, 2025, 7:30 AM EST - 4 months ago

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

EXAS

Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories

Nov 19, 2025, 4:27 PM EST - 4 months ago

Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories

EXAS

Abbott is weighing takeover of Exact Sciences, Bloomberg News reports

Nov 19, 2025, 1:50 PM EST - 4 months ago

Abbott is weighing takeover of Exact Sciences, Bloomberg News reports

EXAS

10 Defensive Stocks with Market-Beating Yields

Nov 8, 2025, 1:10 PM EST - 4 months ago

10 Defensive Stocks with Market-Beating Yields

DG

Abbott Showcases World's First Dual Chamber Leadless Pacemaker in National Media Tour Featuring Patient Story with YourUpdateTV

Oct 30, 2025, 1:00 PM EDT - 4 months ago

Abbott Showcases World's First Dual Chamber Leadless Pacemaker in National Media Tour Featuring Patient Story with YourUpdateTV

Walmart to be first US retailer to sell Abbott's continuous glucose monitor, Axios reports

Oct 21, 2025, 7:34 AM EDT - 5 months ago

Walmart to be first US retailer to sell Abbott's continuous glucose monitor, Axios reports

WMT

These Analysts Revise Their Forecasts On Abbott Following Q3 Results

Oct 16, 2025, 12:50 PM EDT - 5 months ago

These Analysts Revise Their Forecasts On Abbott Following Q3 Results

Gold Gains Over 1%; Abbott Shares Fall After Q3 Results

Oct 15, 2025, 2:20 PM EDT - 5 months ago

Gold Gains Over 1%; Abbott Shares Fall After Q3 Results

Abbott Posts Solid Earnings, Adult Nutrition Drives Sales. The Stock Drops Anyway.

Oct 15, 2025, 8:25 AM EDT - 5 months ago

Abbott Posts Solid Earnings, Adult Nutrition Drives Sales. The Stock Drops Anyway.

Abbott Labs Posts Higher Sales, Reaffirms Outlook

Oct 15, 2025, 7:55 AM EDT - 5 months ago

Abbott Labs Posts Higher Sales, Reaffirms Outlook

Abbott posts higher quarterly revenue on strong medical device demand

Oct 15, 2025, 7:36 AM EDT - 5 months ago

Abbott posts higher quarterly revenue on strong medical device demand

Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance

Oct 15, 2025, 7:30 AM EDT - 5 months ago

Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance

Stock Market Today: Nasdaq, Dow Jones Futures Rise, Bank Of America, Morgan Stanley, Abbott In Focus—Analyst Warns US 'Going Broke Slowly'

Oct 15, 2025, 5:59 AM EDT - 5 months ago

Stock Market Today: Nasdaq, Dow Jones Futures Rise, Bank Of America, Morgan Stanley, Abbott In Focus—Analyst Warns US 'Going Broke Slowly'

BAC MS

TechTraderGrok
TechTraderGrok Mar. 16 at 11:03 PM
Sold $ABT at $109.96 (-0.3%). From Grok: "Recent daily action shows the stock struggling below $110 with lower lows since late February, so we're exiting the 3/11 long to avoid further drawdown. " https://www.techtrader.ai/grokwall/?post=17002&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
DiamondCapital
DiamondCapital Mar. 16 at 1:42 PM
$CVKD Quick DD -17M Market cap Frunexian -Phase 2 ready VLX-1005 - FDA Fast Track, FDA Orphan Drug Tecararin - FDA Fast Track, FDA Orphan Drug, Collab w/ Abbott $ABT •$40B Anticoagulation market •Big players on board of directors •$45 price target by Noble Financial and $32 price target by H.C Wainwright Currently $7.56 per share
0 · Reply
BlowinMaBackOut
BlowinMaBackOut Mar. 15 at 5:15 PM
$MODD currently about 250m shares (including warrants and such)....even a 300m buyout by a big player would be savage...manufacturing just waiting for green light from fda...who's gonna be the buyer? $ABT $MDT other?
0 · Reply
bluffmeariver
bluffmeariver Mar. 11 at 11:17 PM
$ABT how many Libre deaths
0 · Reply
PolycarpFX
PolycarpFX Mar. 11 at 9:01 PM
If 56 breaks cleanly there is risk down to 52 for the Med Device ETF $IHI Saw several dark pool prints hit for holdings within it today $ABT $BSX
0 · Reply
TechTraderGrok
TechTraderGrok Mar. 11 at 8:05 PM
Bought $ABT at $110.34. From Grok: "Re-entering LONG at 110 as ABT's $20B debt raise for EXAS acquisition confirms major bullish catalyst overriding prior technical exit, with supports holding and upside targets to 133." https://www.techtrader.ai/grokwall/?post=16884&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
erevnon
erevnon Mar. 11 at 3:51 PM
Citigroup maintains Abbott Laboratories $ABT at Buy and lowers the price target from $140 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
william2012
william2012 Mar. 10 at 11:05 PM
$ABT 😡😡😡😡😡😡😡😡
1 · Reply
TechTraderGrok
TechTraderGrok Mar. 10 at 8:34 PM
Sold $ABT at $110.61 (-0.3%). From Grok: "Exiting LONG as ABT fails to hold above $111 support with RSI 43 dipping oversold, MACD negative at -0.78/-0.71, price below EMAs amid lack of positive catalysts post-earnings miss." https://www.techtrader.ai/grokwall/?post=16872&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 10 at 7:34 PM
$ABT Share Price: $110.59 Contract Selected: Apr 02, 2026 $110 Calls Buy Zone: $2.76 – $3.41 Target Zone: $4.94 – $6.04 Potential Upside: 69% ROI Time to Expiration: 22 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SebNo1234
SebNo1234 Mar. 10 at 12:08 PM
$BEAT With all the news and good figures on Thursday, this place is going through the roof.🚀🚀🍀🍀👍👍 https://ir.heartbeam.com/?_gl=1*93zdi0*_ga*MTk2ODUwNzkzMy4xNzczMTQzOTQz*_ga_WW8VDXM30P*czE3NzMxNDM5NDMkbzEkZzEkdDE3NzMxNDQ0NDAkajYwJGwwJGgw $ADUS $ACAD $ABT
0 · Reply
Kenito20
Kenito20 Mar. 9 at 2:59 PM
$ABT short here
1 · Reply
jdlman
jdlman Mar. 8 at 8:44 PM
$ABT $CRH $NXPI getting ready to some serious leap calls
0 · Reply
have_to_gain
have_to_gain Mar. 8 at 5:44 AM
$ABT what can be the lower price maybe again 20-106 or lower?
0 · Reply
have_to_gain
have_to_gain Mar. 8 at 5:44 AM
$ABT is this good price to buy this big company?
0 · Reply
Oldpuck
Oldpuck Mar. 6 at 7:10 PM
$ABT All the medical device companies ABT, BSX, MDT, DXCM, PODD, TNDM, EW all down this year. JNJ about the only one that has done well
0 · Reply
ChartSniper33
ChartSniper33 Mar. 6 at 6:06 PM
$ABT absolutely dumpy.
0 · Reply
Alderson95
Alderson95 Mar. 6 at 5:12 AM
$ABT $DXCM $PODD $SENS $TNDM
0 · Reply
JInvestTrade
JInvestTrade Mar. 6 at 4:24 AM
$SENS $DXCM $ABT $TNDM $PODD https://www.linkedin.com/posts/senseonics-incorporated-gets-fda-investigational-share-7434771429893746688-59if?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAACZifW0B2JqOqHkWvrhyPzzcI0ENdA47TYM&utm_campaign=copy_link
0 · Reply
ksoption
ksoption Mar. 5 at 6:28 PM
$ABT
0 · Reply
Estimize
Estimize Mar. 5 at 3:48 PM
Wall St is expecting 1.15 EPS for $ABT Q1 [Reporting 04/22 BMO] http://www.estimize.com/intro/abt?chart=historical&metric_name=eps&utm_cont
0 · Reply